Tag Archives: EOS

Top 5 Medical Stocks For 2019

Thrivent Financial for Lutherans increased its holdings in Steris PLC (NYSE:STE) by 3.8% during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 19,289 shares of the medical equipment provider’s stock after buying an additional 714 shares during the quarter. Thrivent Financial for Lutherans’ holdings in Steris were worth $1,801,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also bought and sold shares of the stock. BlackRock Inc. boosted its holdings in shares of Steris by 3.4% in the fourth quarter. BlackRock Inc. now owns 7,184,409 shares of the medical equipment provider’s stock worth $628,419,000 after buying an additional 239,200 shares during the last quarter. Massachusetts Financial Services Co. MA boosted its holdings in shares of Steris by 8.4% in the first quarter. Massachusetts Financial Services Co. MA now owns 2,164,389 shares of the medical equipment provider’s stock worth $202,068,000 after buying an additional 168,528 shares during the last quarter. ArrowMark Colorado Holdings LLC boosted its holdings in shares of Steris by 0.8% in the fourth quarter. ArrowMark Colorado Holdings LLC now owns 1,487,376 shares of the medical equipment provider’s stock worth $130,101,000 after buying an additional 11,742 shares during the last quarter. American Century Companies Inc. lifted its holdings in Steris by 9.2% during the first quarter. American Century Companies Inc. now owns 1,304,248 shares of the medical equipment provider’s stock valued at $121,765,000 after purchasing an additional 110,081 shares in the last quarter. Finally, Victory Capital Management Inc. purchased a new position in Steris during the first quarter valued at approximately $114,441,000. 91.03% of the stock is currently owned by institutional investors.

Top 5 Medical Stocks For 2019: Bruker Corporation(BRKR)

Advisors’ Opinion:

  • [By Max Byerly]

    Get a free copy of the Zacks research report on Bruker (BRKR)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Shane Hupp]

    Get a free copy of the Zacks research report on Bruker (BRKR)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Ethan Ryder]

    Get a free copy of the Zacks research report on Bruker (BRKR)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

Top 5 Medical Stocks For 2019: LaSalle Hotel Properties(LHO)

Advisors’ Opinion:

  • [By Joseph Griffin]

    Boenning Scattergood reaffirmed their hold rating on shares of LaSalle Hotel Properties (NYSE:LHO) in a research report report published on Friday.

  • [By Max Byerly]

    Mackay Shields LLC bought a new stake in shares of LaSalle Hotel Properties (NYSE:LHO) in the 1st quarter, according to its most recent 13F filing with the SEC. The firm bought 48,225 shares of the real estate investment trust’s stock, valued at approximately $1,399,000.

  • [By Stephan Byrd]

    Get a free copy of the Zacks research report on LaSalle Hotel Properties (LHO)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Matthew DiLallo]

    One other item to keep an eye on is the company’s attempts to acquire rival LaSalle Hotel Properties (NYSE:LHO). Pebblebrook has made three unsolicited offers; the latest and final one was for $32.49 per share, which is a 33.2% premium to LaSalle’s stock before Pebblebrook made its first offer of $29.95 a share a month ago. Pebblebrook has already strategically purchased 4.8% of LaSalle’s outstanding shares in hopes of pushing toward an agreement.

  • [By Paul Ausick]

    LaSalle Hotel Properties (NYSE: LHO) fell about 14% Wednesday to post a new 52-week low of $24.00 after closing at $28.25 on Tuesday. The 52-week high is $31.75. Volume of about 12.2 million was more than 10 times the daily average. The company’s results were hit hard by Hurricane Irma.

Top 5 Medical Stocks For 2019: Eaton Vance Enhanced Equity Income Fund II(EOS)

Advisors’ Opinion:

  • [By Stephan Byrd]

    EOS (CURRENCY:EOS) traded 4.1% higher against the US dollar during the 24 hour period ending at 14:00 PM E.T. on June 27th. EOS has a total market capitalization of $7.24 billion and $772.07 million worth of EOS was traded on exchanges in the last 24 hours. Over the last week, EOS has traded down 22.9% against the US dollar. One EOS token can currently be purchased for approximately $8.08 or 0.00131687 BTC on major cryptocurrency exchanges including Kuna, Bibox, Cryptopia and CoinExchange.

  • [By Shane Hupp]

    EOS (CURRENCY:EOS) traded up 9.3% against the US dollar during the 1 day period ending at 20:00 PM E.T. on July 2nd. During the last week, EOS has traded up 8.5% against the US dollar. One EOS token can now be purchased for $8.89 or 0.00135160 BTC on exchanges including Zebpay, CoinEx Market, ChaoEX and Tidex. EOS has a market cap of $7.96 billion and $1.02 billion worth of EOS was traded on exchanges in the last day.

  • [By Ethan Ryder]

    EOS (CURRENCY:EOS) traded 2.8% lower against the dollar during the 24-hour period ending at 23:00 PM E.T. on August 25th. In the last week, EOS has traded down 4% against the dollar. EOS has a total market capitalization of $4.43 billion and approximately $344.84 million worth of EOS was traded on exchanges in the last 24 hours. One EOS coin can now be bought for about $4.89 or 0.00073541 BTC on popular exchanges including Kucoin, Mercatox, ChaoEX and Bitfinex.

  • [By Joseph Griffin]

    EOS (CURRENCY:EOS) traded 0.7% higher against the U.S. dollar during the 1 day period ending at 16:00 PM ET on July 4th. In the last seven days, EOS has traded 13.1% higher against the U.S. dollar. One EOS token can now be purchased for approximately $9.05 or 0.00135304 BTC on major cryptocurrency exchanges including DragonEX, ChaoEX, Hotbit and HitBTC. EOS has a market cap of $8.11 billion and approximately $912.71 million worth of EOS was traded on exchanges in the last 24 hours.

Top 5 Medical Stocks For 2019: Mitel Networks Corporation(MITL)

Advisors’ Opinion:

  • [By Max Byerly]

    Mitel Networks Corp (NASDAQ:MITL) (TSE:MNW) saw a significant drop in short interest in May. As of May 31st, there was short interest totalling 860,264 shares, a drop of 26.0% from the May 15th total of 1,162,149 shares. Approximately 0.7% of the shares of the stock are short sold. Based on an average daily trading volume, of 2,306,634 shares, the short-interest ratio is presently 0.4 days.

  • [By Lisa Levin] Gainers
    SemiLEDs Corporation (NASDAQ: LEDS) shares rose 35.8 percent to $4.55.
    EVINE Live Inc. (NASDAQ: EVLV) gained 28.8 percent to $1.04. The pay-TV home shopping company was named as a potential acquisition target by TechCrunch. According to the publication, Amazon.com, Inc. (NASDAQ: AMZN) is exploring ways of marketing its products and services to consumers beyond the internet.
    Sanmina Corp (NASDAQ: SANM) shares surged 19.1 percent to $33.00 as the company reported stronger-than-expected earnings for its second quarter on Monday.
    Heidrick & Struggles International, Inc. (NASDAQ: HSII) gained 14.9 percent to $37.22 as the company posted upbeat results for its first quarter.
    Santander Consumer USA Holdings Inc. (NYSE: SC) shares climbed 14 percent to $17.90 following upbeat quarterly earnings.
    Helix Energy Solutions Group, Inc. (NYSE: HLX) climbed 14 percent to $7.12 following strong quarterly results.
    Check-Cap Ltd. (NASDAQ: CHEK) gained 13.6 percent to $8.25.
    Atossa Genetics Inc. (NASDAQ: ATOS) rose 11.8 percent to $3.34. Atossa Genetics disclosed that it has Received positive interim review from the Independent Safety Committee in Phase 1 Topical endoxifen dose escalation study in men.
    Cadence Design Systems, Inc. (NASDAQ: CDNS) gained 11.6 percent to $40.99 after the company posted upbeat Q1 results and issued a strong Q2 forecast.
    Genprex, Inc. (NASDAQ: GNPX) climbed 11.2 percent to $4.9363.
    Mitel Networks Corporation (NASDAQ: MITL) rose 10.5 percent to $11.23 after the company agreed to be acquired by affiliates of Searchlight Capital Partners for $2.0 billion.
    Systemax Inc. (NYSE: SYX) rose 10.2 percent to $30.86. Sidoti & Co. upgraded Systemax from Neutral to Buy.
    Orchids Paper Products Company (NYSE: TIS) surged 9.2 percent to $7.13. Orchids Paper Products is expected to report its Q1 financial results on Wednesday, April 25, 2018.
    New Oriental Education & Technology Group Inc. (NYSE: EDU) rose
  • [By Max Byerly]

    Commscope (NASDAQ:COMM) and Mitel Networks (NASDAQ:MITL) are both computer and technology companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, earnings, valuation, profitability, risk and dividends.

  • [By Max Byerly]

    GAM Holding AG bought a new position in shares of Mitel Networks Corp (NASDAQ:MITL) (TSE:MNW) during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 245,367 shares of the communications equipment provider’s stock, valued at approximately $2,692,000. GAM Holding AG owned approximately 0.20% of Mitel Networks at the end of the most recent reporting period.

Top 5 Medical Stocks For 2019: Lowe’s Companies Inc.(LOW)

Advisors’ Opinion:

  • [By Demitrios Kalogeropoulos]

    Marvin Ellison hasn’t had many opportunities to report good news to Lowe’s (NYSE:LOW) investors since he took over the CEO spot last year. The former Home Depot (NYSE:HD) executive announced a reduced sales outlook in each of his first two quarters at the helm, in fact, while noting that execution problems were hurting the chain’s sales and profit trends through most of 2018.

  • [By Daniel B. Kline]

    Lowe’s (NYSE:LOW) has stumbled a bit in recent quarters — that is, relative to the chain’s own high standards.

    The home improvement retailer delivered diluted earnings per share of $1.86 for its second quarter, up from $1.68 in the year-ago period. Overall sales rose by 7.1% to $20.9 billion, and comparable store sales climbed by 5.3%.

  • [By ]

    Technology is at the core of Home Depot’s (HD) continued growth, and it’s why the company announced today that it aims to hire another 1,000 tech professionals to help it pull even further away from rivals like Lowe’s (LOW) .

Top 10 Medical Stocks To Watch For 2019

Zacks Investment Research upgraded shares of UQM Technologies (NYSEAMERICAN:UQM) from a hold rating to a buy rating in a research note released on Saturday morning. They currently have $1.75 target price on the industrial goods maker’s stock.

According to Zacks, “UQM Technologies, Inc. is a developer and manufacturer of power dense, high efficiency electric motors, generators and power electronic controllers for the automotive, aerospace, medical, military and industrial markets. A major emphasis of the Company is developing products for the alternative energy technologies sector including propulsion systems for electric, hybrid electric, plug-in hybrid electric and fuel cell electric vehicles, under-the-hood power accessories and other vehicle auxiliaries and distributed power generation applications. The Company’s headquarters, engineering and product development center, and motor manufacturing operation are located in Frederick, Colorado. “

Top 10 Medical Stocks To Watch For 2019: CytomX Therapeutics, Inc.(CTMX)

Advisors’ Opinion:

  • [By Ethan Ryder]

    Get a free copy of the Zacks research report on CytomX Therapeutics (CTMX)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Ethan Ryder]

    CytomX Therapeutics Inc (NASDAQ:CTMX) CEO Sean A. Mccarthy sold 2,028 shares of the company’s stock in a transaction on Tuesday, July 3rd. The shares were sold at an average price of $25.09, for a total transaction of $50,882.52. Following the completion of the sale, the chief executive officer now owns 84,091 shares of the company’s stock, valued at approximately $2,109,843.19. The transaction was disclosed in a filing with the SEC, which can be accessed through this link.

  • [By Max Byerly]

    Get a free copy of the Zacks research report on CytomX Therapeutics (CTMX)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Chris Lange]

    CytomX Therapeutics Inc. (NASDAQ: CTMX) is presenting on a couple different topics: probody conjugate (CX-2009) treatment in patients with advanced solid tumors and probody drug conjugate targeting CD166 in preclinical antitumor activity. Wedbush has an Outperform rating with a price target of $25, implying upside of 123% from Friday’s closing price of $11.22. The shares have a 52-week range of $10.91 to $35.00. The stock has a consensus price target of $29.20.

  • [By Shane Hupp]

    Shares of CytomX Therapeutics (NASDAQ:CTMX) have earned an average recommendation of “Buy” from the thirteen research firms that are currently covering the firm, MarketBeat reports. Four analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. The average 12-month price target among brokers that have issued ratings on the stock in the last year is $39.86.

Top 10 Medical Stocks To Watch For 2019: Eaton Vance Enhanced Equity Income Fund II(EOS)

Advisors’ Opinion:

  • [By Shane Hupp]

    EOS (CURRENCY:EOS) traded up 9.3% against the US dollar during the 1 day period ending at 20:00 PM E.T. on July 2nd. During the last week, EOS has traded up 8.5% against the US dollar. One EOS token can now be purchased for $8.89 or 0.00135160 BTC on exchanges including Zebpay, CoinEx Market, ChaoEX and Tidex. EOS has a market cap of $7.96 billion and $1.02 billion worth of EOS was traded on exchanges in the last day.

  • [By Ethan Ryder]

    EOS (CURRENCY:EOS) traded 2.8% lower against the dollar during the 24-hour period ending at 23:00 PM E.T. on August 25th. In the last week, EOS has traded down 4% against the dollar. EOS has a total market capitalization of $4.43 billion and approximately $344.84 million worth of EOS was traded on exchanges in the last 24 hours. One EOS coin can now be bought for about $4.89 or 0.00073541 BTC on popular exchanges including Kucoin, Mercatox, ChaoEX and Bitfinex.

  • [By Joseph Griffin]

    EOS (CURRENCY:EOS) traded 0.7% higher against the U.S. dollar during the 1 day period ending at 16:00 PM ET on July 4th. In the last seven days, EOS has traded 13.1% higher against the U.S. dollar. One EOS token can now be purchased for approximately $9.05 or 0.00135304 BTC on major cryptocurrency exchanges including DragonEX, ChaoEX, Hotbit and HitBTC. EOS has a market cap of $8.11 billion and approximately $912.71 million worth of EOS was traded on exchanges in the last 24 hours.

  • [By Stephan Byrd]

    EOS (CURRENCY:EOS) traded 4.1% higher against the US dollar during the 24 hour period ending at 14:00 PM E.T. on June 27th. EOS has a total market capitalization of $7.24 billion and $772.07 million worth of EOS was traded on exchanges in the last 24 hours. Over the last week, EOS has traded down 22.9% against the US dollar. One EOS token can currently be purchased for approximately $8.08 or 0.00131687 BTC on major cryptocurrency exchanges including Kuna, Bibox, Cryptopia and CoinExchange.

Top 10 Medical Stocks To Watch For 2019: Codexis, Inc.(CDXS)

Advisors’ Opinion:

  • [By Logan Wallace]

    Codexis (NASDAQ:CDXS) was downgraded by analysts at ValuEngine from a “strong-buy” rating to a “buy” rating in a research report issued to clients and investors on Monday.

  • [By Keith Noonan, Daniel Miller, and Maxx Chatsko]

    Having even a few of these companies working in your favor over the long term can be a life-changing event. To help put readers on to some high-growth stocks that still have big potential, we asked three Motley Fool investors to profile a top growth investment. Read on to see why they identified Codexis (NASDAQ:CDXS), Activision Blizzard (NASDAQ:ATVI), and Control4 Corporation (NASDAQ:CTRL) as top stocks for growth-seeking investors.

  • [By Ethan Ryder]

    Codexis, Inc. (NASDAQ:CDXS) SVP James Lalonde sold 15,000 shares of the stock in a transaction on Tuesday, July 17th. The stock was sold at an average price of $15.40, for a total value of $231,000.00. Following the sale, the senior vice president now owns 202,566 shares in the company, valued at approximately $3,119,516.40. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

  • [By Jason Hall, Chuck Saletta, and Maxx Chatsko]

    And while investors shouldn’t count Elon Musk and Tesla out, it’s never wise to put all your hopes — and money — on a single company. We asked three investors who write for The Motley Fool — one of whom is a Tesla shareholder — for alternative ideas — stocks they think could put Tesla’s future returns to shame. They put together compelling arguments for Clean Energy Fuels Corp. (NASDAQ:CLNE), Berkshire Hathaway Inc. (NYSE:BRK-A)(NYSE:BRK-B), and Codexis, Inc. (NASDAQ:CDXS). 

  • [By Max Byerly]

    Get a free copy of the Zacks research report on Codexis (CDXS)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Shane Hupp]

    Codexis (NASDAQ:CDXS) hit a new 52-week high and low during trading on Monday . The company traded as low as $14.45 and last traded at $13.98, with a volume of 520808 shares traded. The stock had previously closed at $13.50.

Top 10 Medical Stocks To Watch For 2019: Pluristem Therapeutics Inc.(PSTI)

Advisors’ Opinion:

  • [By Shane Hupp]

    Get a free copy of the Zacks research report on Pluristem Therapeutics (PSTI)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Stephan Byrd]

    Here are some of the news headlines that may have impacted Accern’s rankings:

    Get Pluristem Therapeutics alerts:

    Pluristem Therapeutics Inc. (PSTI) Given Consensus Rating of “Buy” by Analysts (americanbankingnews.com) Head-To-Head Analysis: Pluristem Therapeutics (PSTI) & Amgen (AMGN) (americanbankingnews.com) Pre-Eclampsia Treatment Market Outlook 2025, Global Opportunity & Growth Analysis, Key Players – Alnylam … (menafn.com) Flickering Three Stocks: Golden Star Resources Ltd. (NYSE:GSS), Pluristem Therapeutics Inc. (NASDAQ:PSTI … (thestreetpoint.com) Pluristem Therapeutics Inc. (PSTI) moves -0.72% higher to SMA-50 (nasdaqplace.com)

    Pluristem Therapeutics stock traded up $0.01 during trading hours on Monday, reaching $1.37. The stock had a trading volume of 3,754 shares, compared to its average volume of 201,217. The firm has a market cap of $150.78 million, a PE ratio of -4.28 and a beta of 0.32. Pluristem Therapeutics has a 52 week low of $1.12 and a 52 week high of $2.12.

  • [By Stephan Byrd]

    Pluristem Therapeutics Inc. (NASDAQ:PSTI) has been given a consensus recommendation of “Buy” by the six brokerages that are presently covering the firm, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and four have assigned a buy rating to the company. The average 1 year target price among brokers that have covered the stock in the last year is $4.00.

  • [By Max Byerly]

    Get a free copy of the Zacks research report on Pluristem Therapeutics (PSTI)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

Top 10 Medical Stocks To Watch For 2019: Liberty Tax, Inc.(TAX)

Advisors’ Opinion:

  • [By Stephan Byrd]

    Acacia Research (NASDAQ: ACTG) and Liberty Tax (NASDAQ:TAX) are both small-cap business services companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, dividends, analyst recommendations, profitability, risk, earnings and valuation.

Top 10 Medical Stocks To Watch For 2019: TESARO, Inc.(TSRO)

Advisors’ Opinion:

  • [By Chris Lange]

    Buy-dip on several “Potential Blockbusters” Aimmune Therapeutics, Inc. (NASDAQ: AIMT), Audentes Therapeutics, Inc. (NASDAQ: BOLD), AveXis, Inc. (NASDAQ: AVXS), Bluebird Bio, Inc. (NASDAQ: BLUE), Esperion Therapeutics, Inc. (NASDAQ: ESPR), and Sage Therapeutics, Inc. (NASDAQ: SAGE) are buy-dip candidates given their bullish trends and favorable technical patterns. Intercept Pharmaceuticals, Inc. (NASDAQ: ICPT), Prothena Corp. PLC (NASDAQ: PRTA), Tesaro, Inc. (NASDAQ: TSRO) and Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) have bearish set-ups. Heron Therapeutics, Inc. (NASDAQ: HRTX) is bigger picture bullish, but may correct further on a move below $19.55. Clovis Oncology, Inc. (NASDAQ: CLVS) has bearish set-up and bulls need to push above $69 to invalidate.

  • [By Logan Wallace]

    TESARO Inc (NASDAQ:TSRO) Director Lawrence M. Alleva sold 7,142 shares of the firm’s stock in a transaction dated Tuesday, June 12th. The stock was sold at an average price of $43.11, for a total transaction of $307,891.62. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

  • [By Todd Campbell]

    Tesaro, Inc. (NASDAQ:TSRO) markets a highly successful therapy for ovarian cancer, Zejula, and its plans for the future include winning approval of Zejula’s use alongside another one of its drugs, TSR-042, in non-small cell lung cancer. Will this combination therapy reshape how oncologists treat lung cancer?

  • [By Paul Ausick]

    Tesaro Inc. (NASDAQ: TSRO) traded down more than 10% Wednesday and posted a new 52-week low of $44.51 after closing Tuesday at $49.63. The stock’s 52-week high is $168.92. Volume totaled around 3 million, approaching three times the daily average of around 1.1 million. European banks were hit hard by events in Italy, but Santander had no specific news.

  • [By Cory Renauer]

    All of these biotech stocks have been battered for different reasons, and bouncing back will be a lot easier for some than for others. 

    Company (Symbol) One-Month Loss  Market Capitalization
    Idera Pharmaceuticals (NASDAQ:IDRA) (35%) $199.7 million
    Spark Therapeutics (NASDAQ:ONCE) (38%) $2.16 billion
    Tesaro (NASDAQ:TSRO) (40%) $1.49 billion

    Here’s what needs to happen if these stocks are going to mount a comeback.

  • [By Ethan Ryder]

    TESARO (NASDAQ:TSRO)‘s stock had its “hold” rating reissued by stock analysts at Jefferies Financial Group in a report issued on Friday. They presently have a $38.00 price target on the biopharmaceutical company’s stock. Jefferies Financial Group’s price objective indicates a potential upside of 7.71% from the company’s current price.

Top 10 Medical Stocks To Watch For 2019: Quality Systems, Inc.(QSII)

Advisors’ Opinion:

  • [By Stephan Byrd]

    Get a free copy of the Zacks research report on Quality Systems (QSII)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Max Byerly]

    Connor Clark & Lunn Investment Management Ltd. grew its position in shares of Quality Systems, Inc. (NASDAQ:QSII) by 493.0% during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The fund owned 82,275 shares of the company’s stock after purchasing an additional 68,400 shares during the quarter. Connor Clark & Lunn Investment Management Ltd. owned approximately 0.13% of Quality Systems worth $1,604,000 as of its most recent filing with the SEC.

  • [By Ethan Ryder]

    Get a free copy of the Zacks research report on Quality Systems (QSII)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Lisa Levin]

    Shares of Quality Systems, Inc. (NASDAQ: QSII) got a boost, shooting up 14 percent to $17.08 after the company posted better-than-expected FQ4 results.

  • [By Lisa Levin]

     

    Companies Reporting After The Bell
    Ross Stores, Inc. (NASDAQ: ROST) is projected to post quarterly earnings at $1.07 per share on revenue of $3.54 billion.
    Autodesk, Inc. (NASDAQ: ADSK) is expected to post quarterly earnings at $0.03 per share on revenue of $557.65 million.
    Gap, Inc. (NYSE: GPS) is projected to post quarterly earnings at $0.46 per share on revenue of $3.60 billion.
    Quality Systems, Inc. (NASDAQ: QSII) is estimated to post quarterly earnings at $0.13 per share on revenue of $131.95 million.
    Splunk Inc. (NASDAQ: SPLK) is expected to post quarterly loss at $0.09 per share on revenue of $297.67 million.
    Shoe Carnival, Inc. (NASDAQ: SCVL) is projected to post quarterly earnings at $0.71 per share on revenue of $262.02 million.
    Deckers Outdoor Corporation (NYSE: DECK) is expected to post quarterly earnings at $0.19 per share on revenue of $375.41 million.
    Zoe's Kitchen, Inc. (NYSE: ZOES) is estimated to post quarterly loss at $0.01 per share on revenue of $105.30 million.
    DXC Technology Company (NYSE: DXC) is expected to post quarterly earnings at $2.23 per share on revenue of $6.12 billion.
    8×8, Inc. (NASDAQ: EGHT) is estimated to post quarterly loss at $0.05 per share on revenue of $76.93 million.
    Viasat, Inc. (NASDAQ: VSAT) is projected to post quarterly loss at $0.45 per share on revenue of $424.46 million.
    ePlus inc. (NASDAQ: PLUS) is estimated to post quarterly earnings at $1.01 per share on revenue of $1.60 billion.
    Lions Gate Entertainment Corp. (NYSE: LGF.A) is expected to post quarterly loss at $0.04 per share on revenue of $1.04 billion.
    Agilysys, Inc. (NASDAQ: AGYS) is estimated to post quarterly loss at $0.08 per share on revenue of $32.58 million.
    Nutanix, Inc. (NASDAQ: NTNX) is estimated to post quarterly loss at $0.19 per share on revenue of $278.98 million.
    Veeva Systems Inc. (NYSE: VEEV) is projected to post quarterly earnings at $0.31 per share on revenue

Top 10 Medical Stocks To Watch For 2019: Ultralife Corporation(ULBI)

Advisors’ Opinion:

  • [By Shane Hupp]

    Polar Power (NASDAQ: POLA) and Ultralife (NASDAQ:ULBI) are both small-cap utilities companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, risk, institutional ownership, profitability, earnings, dividends and valuation.

Top 10 Medical Stocks To Watch For 2019: HMS Holdings Corp(HMSY)

Advisors’ Opinion:

  • [By Max Byerly]

    Stock analysts at Chardan Capital initiated coverage on shares of HMS (NASDAQ:HMSY) in a report issued on Thursday, Marketbeat.com reports. The brokerage set a “neutral” rating and a $35.00 price target on the business services provider’s stock. Chardan Capital’s price target would indicate a potential upside of 3.67% from the stock’s current price.

  • [By Logan Wallace]

    HMS Holdings Corp (NASDAQ:HMSY) has earned an average recommendation of “Buy” from the eleven analysts that are currently covering the firm, MarketBeat Ratings reports. Two research analysts have rated the stock with a hold recommendation, seven have given a buy recommendation and one has given a strong buy recommendation to the company. The average 12-month price objective among brokers that have issued a report on the stock in the last year is $30.13.

  • [By Shane Hupp]

    HMS Holdings Corp (NASDAQ:HMSY) has earned a consensus rating of “Buy” from the thirteen analysts that are presently covering the firm, MarketBeat.com reports. Three analysts have rated the stock with a hold recommendation, seven have assigned a buy recommendation and two have given a strong buy recommendation to the company. The average 1 year target price among brokers that have updated their coverage on the stock in the last year is $22.86.

  • [By Logan Wallace]

    Massachusetts Financial Services Co. MA increased its position in shares of HMS Holdings (NASDAQ:HMSY) by 40.9% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 1,007,174 shares of the business services provider’s stock after purchasing an additional 292,456 shares during the period. Massachusetts Financial Services Co. MA owned approximately 1.21% of HMS worth $16,961,000 as of its most recent filing with the Securities and Exchange Commission.

  • [By Max Byerly]

    Macquarie Group Ltd. raised its stake in shares of HMS Holdings Corp (NASDAQ:HMSY) by 344.4% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 8,000 shares of the business services provider’s stock after buying an additional 6,200 shares during the period. Macquarie Group Ltd.’s holdings in HMS were worth $173,000 as of its most recent SEC filing.

  • [By Lisa Levin] Gainers
    Biostar Pharmaceuticals, Inc. (NASDAQ: BSPM) shares jumped 29.86 percent to close at $2.87 on Friday.
    Commercial Vehicle Group, Inc. (NASDAQ: CVGI) shares gained 28.87 percent to close at $8.75 after reporting upbeat Q1 earnings.
    Mexco Energy Corporation (NYSE: MXC) gained 27.02 percent to close at $5.4744.
    Carbon Black, Inc. (NASDAQ: CBLK) climbed 26 percent to close at $23.94. Carbon Black priced its IPO at $19 per share.
    Portola Pharmaceuticals, Inc. (NASDAQ: PTLA) rose 25.64 percent to close at $42.44 after the FDA approved the company's Andexxa, the only antidote indicated for patients treated with rivaroxaban and apixaban.
    Natural Grocers by Vitamin Cottage, Inc. (NYSE: NGVC) rose 23.19 percent to close at $8.50 after reporting Q2 results.
    California Resources Corporation (NYSE: CRC) shares gained 22.45 percent to close at $31.58 following upbeat Q1 earnings.
    Atomera Incorporated (NASDAQ: ATOM) gained 22.31 percent to close at $6.25 after reporting Q1 results.
    Medifast, Inc. (NYSE: MED) shares jumped 22.27 percent to close at $121.46 after the company reported strong Q1 results and raised its FY18 guidance.
    Jerash Holdings (US), Inc. (NASDAQ: JRSH) gained 20.86 percent to close at $8.46.
    Pandora Media, Inc. (NYSE: P) rose 19.83 percent to close at $6.89 after reporting strong quarterly results.
    Shake Shack Inc (NYSE: SHAK) rose 18.01 percent to close at $55.95 on Friday after the company reported upbeat results for its first quarter and raised its FY18 guidance.
    Super Micro Computer, Inc. (NASDAQ: SMCI) rose 17.73 percent to close at $21.25 after reporting strong preliminary results for the third quarter.
    Schmitt Industries, Inc. (NASDAQ: SMIT) rose 17.41 percent to close at $2.36.
    Titan International, Inc. (NYSE: TWI) shares gained 16.78 percent to close at $12.25 following Q1 earnings.
    Integer Holdings Corporation (NYSE: ITGR) shares rose 14.23 percent to close at $63.40 following Q1 result

Top 10 Medical Stocks To Watch For 2019: InspireMD, Inc.(NSPR)

Advisors’ Opinion:

  • [By Lisa Levin] Gainers
    Oragenics, Inc. (NYSE: OGEN) shares surged 66.67 percent to close at $2.00 on Wednesday after the company’s AG013 for oral mucositis in head and neck cancer patients showed favorable safety profile in mid-stage OM study.
    Sigma Labs, Inc. (NASDAQ: SGLB) shares jumped 49.24 percent to close at $1.97 on Wednesday. Sigma Labs demonstrated proof of concept for closed loop quality control during metal additive manufacturing.
    ASLAN Pharmaceuticals Limited (NASDAQ: ASLN) rose 34.45 percent to close at $9.21. BTIG Research initiated coverage on ASLAN Pharmaceuticals with a Buy rating.
    Dick's Sporting Goods, Inc. (NYSE: DKS) shares rose 25.82 percent to close at $38.35 after the company reported upbeat Q1 earnings and raised FY18 earnings outlook.
    TapImmune, Inc. (NASDAQ: TPIV) rose 24.15 percent to close at $5.09. WBB Securities upgraded TapImmune from Speculative Buy to Buy.
    Legacy Reserves LP (NASDAQ: LGCY) jumped 23.3 percent to close at $5.98 on Wednesday.
    Summer Infant, Inc. (NASDAQ: SUMR) gained 22.92 percent to close at $1.18 after announcing commitment for $60 million credit facility from Bank of America and $17.5 million term loan from Pathlight Capital.
    Cloud Peak Energy Inc. (NYSE: CLD) rose 21.95 percent to close at $4.00.
    SpartanNash Co (NASDAQ: SPTN) gained 21.4 percent to close at $22.92 after the company reported upbeat earnings for its first quarter on Tuesday.
    Motus GI Holdings, Inc. (NASDAQ: MOTS) rose 17.14 percent to close at $5.40.
    Movado Group, Inc. (NYSE: MOV) gained 16.59 percent to close at $49.20 after the company reported better-than-expected Q1 results and raised its guidance.
    Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) climbed 15.61 percent to close at $8.22. Oramed Pharma disclosed that its patent has been allowed in the US for oral administration of proteins.
    Dorian LPG Ltd. (NYSE: LPG) rose 14.89 percent to close at $8.41. Dorian LPG confirmed receipt of unsolicited proposal fr
  • [By Lisa Levin] Gainers
    Sigma Labs, Inc. (NASDAQ: SGLB) shares rose 90.9 percent to $2.52. Sigma Labs demonstrated proof of concept for closed loop quality control during metal additive manufacturing.
    Oragenics, Inc. (NYSE: OGEN) shares surged 58.4 percent to $1.9005 after the company’s AG013 for oral mucositis in head and neck cancer patients showed favorable safety profile in mid-stage OM study.
    Dick's Sporting Goods, Inc. (NYSE: DKS) shares climbed 23.2 percent to $37.5370 after the company reported upbeat Q1 earnings and raised FY18 earnings outlook.
    Summer Infant, Inc. (NASDAQ: SUMR) rose 21.9 percent to $1.17 after announcing commitment for $60 million credit facility from Bank of America and $17.5 million term loan from Pathlight Capital.
    TapImmune, Inc. (NASDAQ: TPIV) jumped 18.8 percent to $4.87. WBB Securities upgraded TapImmune from Speculative Buy to Buy.
    Movado Group, Inc. (NYSE: MOV) gained 17.2 percent to $49.45 after the company reported better-than-expected Q1 results and raised its guidance.
    ASLAN Pharmaceuticals Limited (NASDAQ: ASLN) jumped 16.2 percent to $7.96. BTIG Research initiated coverage on ASLAN Pharmaceuticals with a Buy rating.
    Legacy Reserves LP (NASDAQ: LGCY) rose 15.5 percent to $5.6011.
    InspireMD, Inc. (NYSE: NSPR) gained 13.3 percent to $1.36 following PR announcing sustained benefit of CGuard EPS.
    Immutep Limited (NASDAQ: IMMP) shares climbed 13.2 percent to $2.7724 after the company reported new data from its ongoing TACTI-mel Phase I trial, which evaluated the combination of eftilagimod alpha, its lead compound, with Merck & Co., Inc. (NYSE: MRK)'s Keytruda in unresectable or metastatic melanoma patients, who have had a suboptimal response or had disease progression with keytruda monotherapy..
    SpartanNash Co (NASDAQ: SPTN) rose 12.2 percent to $21.20 after the company reported upbeat earnings for its first quarter on Tuesday.
    Amtech Systems, Inc. (NASDAQ: ASYS) rose 12.1 percent to